American Heart Journal
Volume 155, Issue 2 , Pages 215-223 , February 2008

Design of the Future REvascularization Evaluation in patients with Diabetes mellitus: Optimal management of Multivessel disease (FREEDOM) Trial

  • Michael E. Farkouh, MD, MSc

      Affiliations

    • Mount Sinai School of Medicine, New York, NY
    • Corresponding Author InformationReprint requests: Michael E. Farkouh, MD, MSc, FRCPC, FACC, Mount Sinai School of Medicine, One Gustave L Levy place, Box 1074, New York, NY 10029.
    • ,
  • George Dangas, MD, PhD

      Affiliations

    • Columbia University Medical Center, New York, NY
    • ,
  • Martin B. Leon, MD

      Affiliations

    • Columbia University Medical Center, New York, NY
    • ,
  • Craig Smith, MD

      Affiliations

    • Columbia University Medical Center, New York, NY
    • ,
  • Richard Nesto, MD

      Affiliations

    • Lahey Clinic Medical Center, Burlington, MA
    • ,
  • John B. Buse, MD, PhD

      Affiliations

    • University of North Carolina, Chapel Hill, NC
    • ,
  • David J. Cohen, MD, MSc

      Affiliations

    • St Luke's Hospital/Mid America Heart Institute, Kansas City, MO
    • ,
  • Elizabeth Mahoney, ScD

      Affiliations

    • St Luke's Hospital/Mid America Heart Institute, Kansas City, MO
    • ,
  • Lynn Sleeper, ScD

      Affiliations

    • New England Research Institutes, Watertown, MA
    • ,
  • Spencer King III, MD

      Affiliations

    • Fuqua Heart Center/Piedmont Hospital, Atlanta, GA
    • ,
  • Michael Domanski, MD

      Affiliations

    • National Heart, Lung, and Blood Institute, Bethesda, MD
    • ,
  • Sonja McKinlay, PhD

      Affiliations

    • New England Research Institutes, Watertown, MA
    • ,
  • Valentin Fuster, MD, PhD

      Affiliations

    • Mount Sinai School of Medicine, New York, NY

Received 30 March 2007 ,Accepted 9 October 2007.

References 

  1. Harris MI, Flegal KM, Cowie CC, et al. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The Third National Health and Nutrition Examination Survey, 1988-1994. Diabetes Care. 1998;21:518–524
  2. CDC . Prevalence of overweight and obesity among adults with diagnosed diabetes—United States, 1988-1994 and 1999-2002. MMWR Morb Mortal Wkly Rep. 2004;53:1066–1068
  3. Grundy SM, Benjamin IJ, Burke GL, et al. Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation. 1999;100:1134–1146
  4. Serruys PW, Unger F, Sousa JE, et al. Comparison of coronary-artery bypass surgery and stenting for the treatment of multivessel disease. N Engl J Med. 2001;344:1117–1124
  5. Bakhai A, Stables RH, Prasad S, et al. Trials comparing coronary artery bypass grafting with percutaneous transluminal coronary angioplasty and primary stent implantation in patients with multivessel coronary artery disease. Curr Opin Cardiol. 2000;15:388–394
  6. Abizaid A, Costa MA, Centemero M, et al. Clinical and economic impact of diabetes mellitus on percutaneous and surgical treatment of multivessel coronary disease patients: insights from the Arterial Revascularization Therapy Study (ARTS) trial. Circulation. 2001;104:533–538
  7. Serruys PW, Ong AT, van Herwerden LA, et al. Five-year outcomes after coronary stenting versus bypass surgery for the treatment of multivessel disease: the final analysis of the Arterial Revascularization Therapies Study (ARTS) randomized trial. J Am Coll Cardiol. 2005;46:575–581
  8. Roiron C, Sanchez P, Bouzamondo A, et al. Drug eluting stents: an updated meta-analysis of randomised controlled trials. Heart. 2006;92:641–649[electronic publication 2005 Oct 10. Review]
  9. Stettler C, Allemann S, Egger M, et al. Efficacy of drug eluting stents in patients with and without diabetes mellitus: indirect comparison of controlled trials. Heart. 2006;92:650–657[electronic publication 2005 Oct 26. Review]
  10. Signorini DF, Leung O, Simes RJ, et al. Dynamic balanced randomization for clinical trials. Stat Med. 1993;12:2343–2350
  11. Zelen M. The randomization and stratification of patients to clinical trials. J Chronic Dis. 1974;27:365–375
  12. Morice MC, Serruys PW, Sousa JE, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med. 2002;346:1773–1780[Circulation 2004;110 page 630]
  13. The EuroQol Group. EuroQol—a new facility for the measurement of health-related quality of life.. Health Policy. 1990;16:199–208
  14. Torrance GW. Measurement of health state utilities for economic appraisal. J Health Econ. 1986;5:1–30
  15. Spertus JA, Winder JA, Dewhurst TA, et al. Monitoring the quality of life in patients with coronary artery disease. Am J Cardiol. 1994;74:1240–1244
  16. Rose GA. The diagnosis of ischaemic heart pain and intermittent claudication in field surveys. Bull World Health Organ. 1962;27:645–658
  17. Cleary PD, Epstein AM, Oster G, et al. Health-related quality of life among patients undergoing percutaneous transluminal coronary angioplasty. Med Care. 1991;29:939–950
  18. Taira DA, Seto TB, Siegrist R, et al. Comparison of analytic approaches for the economic evaluation of new technologies alongside multicenter clinical trials. Am Heart J. 2003;145:452–458
  19. Lan KK, DeMets DL. Discrete sequential boundaries for clinical trials. Biometrika. 1983;70:659–663
  20. O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics. 1979;35:549–556
  21. DeMets DL, Lan KK. Interim analysis: the alpha spending function approach. Stat Med. 1994;13:1341–1352[discussion 1353-6]

 This study was sponsored by the National Heart, Lung and Blood Institute, National Institutes of Health (Bethesda, Maryland), grant no. 5U01HL071988.

PII: S0002-8703(07)00825-3

doi: 10.1016/j.ahj.2007.10.012

American Heart Journal
Volume 155, Issue 2 , Pages 215-223 , February 2008

Article Tools

* Image Usage & Resolution